Syndax Announces Participation in May Investor Conferences

Core Insights - Syndax Pharmaceuticals is a commercial-stage biopharmaceutical company focused on innovative cancer therapies [2] - The company has FDA-approved products in its pipeline, including Revuforj® (revumenib) and Niktimvo™ (axatilimab-csfr) [2] - Syndax is actively conducting clinical trials to maximize the potential of its pipeline [2] Upcoming Events - Michael A. Metzger, CEO of Syndax, and the management team will participate in investor conferences [1] - A fireside chat at the Bank of America Merrill Lynch Vegas Health Care Conference is scheduled for May 15, 2025, at 9:20 a.m. PT/12:20 p.m. ET [3] - A virtual fireside chat at the TD Cowen 6th Annual Oncology Innovation Summit will take place on May 28, 2025, at 10:30 a.m. ET [3]